Custom service

Custom Monoclonal Antibody Scale Up

From a frozen vial to grams, without changing the antibody.

Scale: 10 mg–10 g — per production runFormats: Suspension, hollow fibre — or ascitesTimeline: 4–8 weeks — per run

The transition from a T-flask to a production scale is where many hybridoma projects stall. A clone that yields 20 µg/mL in a static flask may yield 100 µg/mL in suspension, or it may not grow at all once the serum is removed. Scale-up begins with adaptation, not with a bigger vessel.

Three production routes cover most needs. Suspension culture in shaker flasks or a stirred-tank bioreactor, adapted to serum-free medium, gives the most reproducible product and the cleanest downstream stream. Hollow-fibre bioreactors keep cells at high density in a small volume and reach 1–5 mg/mL in the harvest, which suits antibodies that grow poorly in suspension. Ascites remains available for mouse hybridomas when only a few millilitres are needed and the regulatory burden is acceptable.

Process parameters are set once and then held: seeding density, pH, dissolved oxygen, feeding strategy and harvest time. A production run is only useful if it can be repeated, so the parameters are documented and the second run is expected to match the first within a defined tolerance.

Service Highlights

Where it fits

Scale-up is required when an antibody moves from feasibility into a product, a diagnostic kit or an in vivo study requiring gram quantities. It is also the right response when a laboratory's own flask culture can no longer meet demand.

It is not economical below about 10 mg, where a single purification from existing supernatant is cheaper, and it is not a substitute for clone optimisation — scaling a low-producing clone multiplies cost rather than solving it.

Documentation and QC

Each run is documented with a batch record covering inoculation density, feeding, metabolite data, harvest viability and purification yields. The product is released with SDS-PAGE, SEC-HPLC, endotoxin and sterility results, and a comparison against the previous run so that batch-to-batch consistency is visible.

Frequently asked questions

How much antibody can one run produce?

From a 5 L suspension culture at 100 mg/L, roughly 400–500 mg after purification. Hollow-fibre runs from the same clone often reach several grams because the harvest concentration is much higher.

Is ascites still acceptable?

For research use in many jurisdictions, yes, though ethical and regulatory acceptance is declining. We recommend in vitro production for anything intended for clinical or diagnostic work.

Can the process be transferred to our facility?

Yes. Batch records, adaptation history and the research cell bank are transferred, and we can run a technical transfer session with your production team.

Tell us the quantity and the timeline. If the clone will not adapt to suspension, hollow fibre is the pragmatic route — and we will say which one applies after the shake-flask evaluation.

Service Highlights

  • Adaptation before scale-up. Four to six passages of stepwise serum reduction, with growth rate and specific productivity measured at each step.
  • Route chosen on the clone. Suspension bioreactor, hollow fibre or ascites, selected according to growth behaviour rather than to convenience.
  • Fed-batch with controlled feeding. Glucose and glutamine maintained within setpoints, with lactate and ammonia monitored to avoid early decline.
  • Harvest timing. Collected at peak viability rather than at culture end, which reduces proteolysis and aggregate content.
  • Documented parameters. PH, DO, agitation, feed schedule and harvest criteria recorded, so the run can be repeated.
  • Downstream included. Clarification, affinity capture and formulation as part of the same work package.

How the work runs

  1. Clone evaluation

    Growth in serum-free medium, specific productivity and aggregation tendency are measured in shake flasks before any large vessel is committed.

  2. Adaptation

    Stepwise serum weaning and suspension adaptation, with a research cell bank prepared at the end of adaptation.

  3. Process development

    Small-scale runs at 250 mL to set feeding strategy, pH and harvest time, with titre and metabolite profiles compared.

  4. Production run

    1–20 L suspension culture or hollow-fibre run, monitored daily, harvested at the defined viability threshold.

  5. Purification

    Clarification, protein A capture, ion exchange and formulation, with yield tracked at each step.

  6. QC and documentation

    Purity, concentration, aggregation, endotoxin, sterility where required, and a batch record describing the process.

Specifications & timeline

Scale
10 mg–10 g — per production run
Formats
Suspension, hollow fibre — or ascites
Timeline
4–8 weeks — per run
Scale
10 mg to 10 g per run; larger on request
Vessels
Shaker flasks, stirred-tank bioreactor 1–20 L, hollow-fibre cartridge
Medium
Serum-free, chemically defined; low-protein options for simplified purification
Titre
Typically 50–500 mg/L in suspension, higher in hollow fibre
Timeline
4–8 weeks per run including adaptation and QC
Deliverables
Purified antibody, batch record, QC certificate, research cell bank

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.